China BCI industry: scaling, policy, and clinical trials

China’s brain-computer interface industry is scaling rapidly from research to commercialization, driven by strong policy support, expanding clinical trials, and growing investor interest.¹
NeuroXess is advancing to human trials with a mix of government backing and investor enthusiasm, positioning to compete with Neuralink.²
China’s BCI industry is being framed as racing ahead of or challenging U.S. dominance in clinical trials and technology.¹
Policy and regulatory fast-tracking are supporting the domestic BCI industry.¹
Elon Musk’s Neuralink has been cited as a catalyst for increased Chinese BCI investment and competitive urgency.¹

Gardner updates

China reports more than 50 human BCI implants and real-time decoding of Chinese speech.¹
Implementation evidence is reported claims, not peer-reviewed.¹
Reuters (via Google News) reported a Beijing-backed brain-chip firm saying it trails Neuralink by about three years—framed as the company’s own comparison rather than independent verification in the briefing excerpt. ³
China Daily coverage (via Google News) states a top scientist is urging global collaboration on BCI development, explicitly naming standards, safety, and shared R&D as part of the diplomatic/policy framing. ⁴
Reuters Connect coverage (via Google News) describes Beinao-1 as a semi-invasive BMI demonstrated on a Beijing media tour, with the brief noting emphasis on demonstration visibility over published trial/spec detail. ⁵
Trade coverage reported StairMed closed a financing round described as about $72.8 million. ⁶
A separate report described the round as about $73 million and tied proceeds to advancing BMI and DBS development. ⁷